Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098131 | 0.93 | KDM1A (0.42) | KDM1ASUV39H2GRM5HCRTR1HCRTR2 | |
| SCHEMBL2098129 | 0.93 | KDM1A (0.42) | KDM1ASUV39H2GRM5HCRTR1HCRTR2 | |
| SCHEMBL13415855 | 0.89 | KDM1A (0.42) | KDM1AUSP2GRM5HSD11B1LMNA | |
| SCHEMBL10287658 | 0.85 | KMT2A (0.44) | — | |
| SCHEMBL1117123 | 0.80 | KMT2A (0.39) | SUV39H2HSD11B1HSD11B2 | |
| SCHEMBL1117119 | 0.80 | KMT2A (0.39) | SUV39H2HSD11B1HSD11B2 | |
| SCHEMBL2620566 | 0.79 | USP2 (0.39) | KDM1AUSP2LMNA | |
| SCHEMBL2612630 | 0.78 | KMT2A (0.37) | USP2SUV39H2HSD11B1LMNAHSD11B2 | |
| SCHEMBL2097985 | 0.78 | KDM4D (0.46) | KDM1AGRM5GPR119 | |
| SCHEMBL2097983 | 0.78 | KDM4D (0.46) | KDM1AGRM5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | KDM1A 780/4885USP2 3074/4885SUV39H2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.